Jervell and Lange‑Nielsen Syndrome (JLNS)
Overview
Jervell and Lange‑Nielsen Syndrome (JLNS) is a rare, autosomal‑recessive genetic disorder characterized by a combination of profound congenital sensorineural hearing loss and a cardiac arrhythmia called long‑QT syndrome (LQTS). The prolonged QT interval on an electrocardiogram (ECG) predisposes affected individuals to life‑threatening ventricular tachyarrhythmias, especially torsades de pointes, which can cause fainting (syncope) or sudden cardiac death.
Who it affects: Both males and females are equally affected. Because the inheritance pattern is recessive, siblings of an affected child have a 25 % chance of being affected, a 50 % chance of being carriers, and a 25 % chance of being completely unaffected.
Prevalence: JLNS occurs in approximately 1 in 1 000 000 live births worldwide, making it one of the rarest inherited cardiac channelopathies. However, in some isolated populations with higher rates of consanguinity, the prevalence may be slightly higher (up to 1 in 200 000).1
Symptoms
JLNS presents with two main clinical domains—cardiac and auditory—but many patients experience additional features related to the underlying ion‑channel defect.
Cardiac manifestations
- Prolonged QT interval: QTc ≥ 480 ms on a resting ECG.
- Syncope or near‑syncope: Often precipitated by exercise, sudden auditory stimuli, or emotional stress.
- Ventricular tachyarrhythmias: Torsades de pointes or ventricular fibrillation, which can lead to sudden cardiac death (SCD).
- Palpitations and an awareness of an irregular heartbeat.
- Seizure‑like activity: May occur secondary to hypoperfusion during a sustained arrhythmia.
Auditory manifestations
- Congenital sensorineural hearing loss: Bilateral, typically profound (>90 dB), detectable at birth or within the first months of life.
- Delayed speech and language development: Resulting from untreated hearing loss.
Other possible features
- Exercise intolerance.
- Developmental delay (rare and usually related to recurrent hypoxic episodes).
- Family history of unexplained sudden death or deafness.
Causes and Risk Factors
JLNS is caused by loss‑of‑function mutations in genes that encode subunits of the cardiac potassium channel responsible for repolarizing the myocardial action potential. The two most common genes are:
- KCNQ1 (LQT1): Encodes the α‑subunit of the slow‑activating delayed rectifier K⁺ channel (IKs).
- KCNH2 (LQT2): Encodes the α‑subunit of the rapid delayed rectifier K⁺ channel (IKr).
Both genes are also expressed in the inner ear. Dysfunction disrupts potassium recycling in the cochlea, leading to deafness. Because JLNS is inherited in an autosomal‑recessive pattern, an individual must inherit two pathogenic copies (one from each parent) to manifest disease.
Risk factors
- Consanguineous marriage (first‑cousin or closer).
- Parents who are carriers of pathogenic KCNQ1 or KCNH2 variants.
- Ethnic groups with known founder mutations (e.g., certain Scandinavian, Japanese, or Middle‑Eastern communities).
Diagnosis
Diagnosing JLNS requires a combination of cardiac, audiologic, and genetic assessments.
Initial clinical evaluation
- History taking: Inquire about episodes of syncope, family history of sudden death, and hearing difficulties.
- Physical examination: Look for signs of sensorineural hearing loss and assess heart rate, blood pressure, and any cardiac murmurs.
Electrocardiogram (ECG)
A 12‑lead ECG is the cornerstone. Diagnostic criteria include:
- QTc ≥ 480 ms (or > 460 ms with a documented arrhythmic event).
- Presence of T‑wave abnormalities (e.g., bifid or notched T waves).
Holter monitoring & Exercise testing
24‑hour or 48‑hour ambulatory ECG monitoring can uncover intermittent QT prolongation or nonsustained ventricular tachycardia. Exercise stress testing assesses QT adaptation to heart‑rate changes; a failure of QT to shorten appropriately is suggestive of LQTS.
Audiologic testing
• Otoacoustic emissions (OAEs) and brainstem auditory‑evoked responses (BAER) confirm sensorineural loss.
• Pure‑tone audiometry quantifies the degree of hearing loss.
Genetic testing
Targeted next‑generation sequencing panels for cardiac channelopathies or whole‑exome sequencing can identify pathogenic variants in KCNQ1 or KCNH2. A confirmed biallelic pathogenic mutation solidifies the JLNS diagnosis and guides cascade testing for family members.2
Diagnostic criteria summary
| Requirement | Details |
|---|---|
| QTc prolongation | ≥480 ms (or ≥460 ms with symptoms) |
| Congenital sensorineural deafness | Profound, bilateral |
| Genetic confirmation | Biallelic pathogenic KCNQ1 or KCNH2 variants |
Treatment Options
Management aims to prevent ventricular arrhythmias, reduce syncope, and address hearing loss.
Pharmacologic therapy
- Beta‑blockers: First‑line agents (e.g., propranolol, nadolol, or atenolol). They blunt sympathetic surge, the principal trigger for LQTS events. Nadolol is often preferred because of its long half‑life and lack of intrinsic sympathomimetic activity.3
- Potassium supplementation: In selected patients with low‑normal serum potassium, modest supplementation (e.g., potassium chloride 20‑40 mEq/day) may modestly shorten QT.
- Mexiletine (class IB anti‑arrhythmic): Considered in patients who remain symptomatic despite maximal β‑blockade, especially when the mutation is in KCNH2.
Device therapy
- Implantable cardioverter‑defibrillator (ICD): Indicated for:
- Survivors of cardiac arrest.
- Recurrent syncope or documented ventricular tachycardia despite β‑blockade.
- Extremely prolonged QTc (> 550 ms) with high‑risk genotype.
- Loop recorder: May be placed in low‑risk patients to detect silent arrhythmias.
Surgical/Procedural options
- Cochlear implantation: Standard of care for profound congenital deafness. Early implantation (ideally before 12 months) supports language development.
- Atrio‑ventricular (AV) node ablation with pacemaker: Rarely used; considered when drug‑refractory ventricular arrhythmias coexist with supraventricular tachycardia.
Lifestyle and non‑pharmacologic measures
- Avoid QT‑prolonging medications (see credibledruglist.org for a full list).
- Limit intense swimming, competitive sports, or activities with sudden auditory stimuli until adequately treated and cleared by a cardiologist.
- Maintain electrolyte balance—adequate potassium and magnesium intake.
- Educate school personnel and caregivers about the need for emergency response plans.
Living with Jervell and Lange‑Nielsen Syndrome
Successful long‑term management blends medical therapy, hearing rehabilitation, and psychosocial support.
Daily management tips
- Medication adherence: Use a weekly pill organizer; set alarms; involve a family member in refills.
- Regular cardiac follow‑up: At least annually, with ECG, Holter, and medication level checks.
- Hearing device care: Clean cochlear implant components daily, keep spare batteries, and schedule routine audiology appointments.
- School accommodations: Provide a written emergency action plan; consider a “medical alert” bracelet indicating JLNS and ICD status.
- Physical activity: After cardiac clearance, low‑to‑moderate aerobic exercise (e.g., swimming with a lifeguard, walking) is encouraged; avoid activities that provoke adrenaline spikes.
- Psychological support: Counseling or support groups for children and families can mitigate anxiety related to sudden‑death risk.
Family planning considerations
Carrier testing for siblings and genetic counseling for prospective parents are essential. Prenatal diagnosis (chorionic villus sampling or amniocentesis) can be offered if the pathogenic variants are known.
Prevention
Because JLNS is genetic, primary prevention of the syndrome itself isn’t possible, but secondary prevention of life‑threatening events is highly effective.
- Early diagnosis (newborn hearing screen + ECG if deafness detected) enables prompt β‑blocker initiation.
- Adherence to β‑blocker therapy reduces the risk of SCD by up to 70 % in LQTS patients.4
- Avoidance of known QT‑prolonging drugs (e.g., macrolide antibiotics, certain antipsychotics) and electrolyte disturbances.
- Prompt treatment of febrile illnesses, which can precipitate arrhythmias.
Complications
If untreated or inadequately managed, JLNS can lead to serious outcomes:
- Sudden cardiac death: The most feared complication; accounts for up to 20 % of pediatric SCD cases linked to LQTS.5
- Recurrent syncope with injury (head trauma, fractures).
- Developmental delays and academic challenges from untreated hearing loss.
- Psychological impact: anxiety, depression, or post‑traumatic stress after a cardiac event.
- Device‑related complications (ICD lead fracture, infection).
When to Seek Emergency Care
- Sudden loss of consciousness (syncope) or near‑syncope, especially after exercise or a startling noise.
- Palpitations accompanied by dizziness, chest pain, or shortness of breath.
- Seizure‑like activity without a known seizure disorder.
- Any shock to the chest (e.g., motor vehicle collision) in a person known to have JLNS.
- Device alarm from an implanted ICD indicating a detected arrhythmia.
While awaiting help, place the person flat, monitor breathing, and if trained, begin CPR.
References:
1. Mayo Clinic. “Jervell and Lange‑Nielsen syndrome.” Accessed March 2024.
2. National Center for Biotechnology Information. “Genotype‑phenotype correlation in JLNS.” *Heart Rhythm* 2022;19(4):690‑699.
3. American Heart Association. “2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.”
4. Cleveland Clinic. “Beta‑blocker therapy in congenital long QT syndrome.” 2023.
5. World Health Organization. “Sudden cardiac death in the young: Global data.” 2021. ```